Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 57Ovarian Neoplasms 37Carcinoma, Hepatocellular 35Neoplasms 25Fallopian Tube Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Endometrial Neoplasms 13Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Colonic Neoplasms 9Uterine Cervical Neoplasms 8Lung Neoplasms 8Liver Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite-stable Colorectal Cancer × Bevacizumab × 90 days × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡